research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
Search
for
Sort by
Research
360-390 / 1000+ results
research Formulation of a film-coated dutasteride tablet bioequivalent to a soft gelatin capsule (Avodart®): Effect of γ-cyclodextrin and solubilizers
Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Dr Reddy's Laboratories has announced the launch of its finasteride and simvastatin tablets,
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study
Baricitinib and ritlecitinib are both effective and safe for treating severe alopecia areata.
research Peripheral neuropathy associated with tofacitinib use in alopecia universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
research Straight hair associated with interferon-alfa plus ribavirin in hepatitis C infection
ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Anti-DFS70 sebagai Penanda Kejadian Autoimun Nonsistemik (Primary Billiar Cholangitis) pada Systemic Lupus Erythematosus
Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection
Dextran sulfate was found to be toxic and ineffective for treating HIV.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
Adalimumab improved folliculitis decalvans in most patients.
research Baricitinib as a treatment for myasthenia gravis: A case report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.